Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breathing in a special gas: a new MRI lens on lung fibrosis treatment

NCT ID NCT07786090

Knowledge-focused Sponsor: Dr. Grace Parraga Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This observational study explores whether a specialized MRI technique using inhaled hyperpolarized xenon gas can detect how approved antifibrotic therapies affect the lungs of adults with fibrotic interstitial lung disease. Researchers will compare imaging changes with standard tests like breathing tests and walking distance to see if the MRI can reveal treatment effects. The goal is to better understand the relationship between clinical response and imaging response, potentially improving how treatment success is measured.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hyperpolarized 129Xe gas inhaled for MRI imaging
What this could lead to
If successful, this could establish advanced MRI as a sensitive tool to monitor therapy response in fibrotic lung disease, potentially guiding more personalized treatment decisions.
What could go wrong
This is a small observational study, so results may not apply broadly. The imaging technique is specialized and may not be widely available, and it may not clearly distinguish treatment responders from non-responders.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be adults 18-80 years of age with physician-diagnosed fibrotic interstitial lung disease consistent with 2022 ATS/ERS guidelines and are eligible for antifibrotic therapy. Participants will be referred from respirologists at LHSC London outpatient respirology clinics.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature. * Provision of written, informed consent prior to any study specific procedures. * Males and females \>/= 18 years of age * Patient has a current diagnosis of fILD by a respirologist according to the 2022 ATS/ERS guidelines and is eligible for antifibrotic therapy. * Women of childbearing potential must ensure that they are using an effective form of birth control for at least 2 months prior to each imaging visit. * Women of childbearing potential must agree to use a highly effective form of birth control from enrollment, throughout the study duration, with negative urine pregnancy test result at Visits 1, 2, and 3. Exclusion Criteria: * Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) * In the investigator's opinion, subject suffers from any physical, psychological or other conditions that might prevent performance of the MRI or CT, such as severe claustrophobia. * Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit. * Participant is unable to perform spirometry or plethysmography maneuvers. * Participant is unable to perform MRI and CT breath-hold maneuvers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibrotic interstitial lung disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fibrotic interstitial lung disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre

    London, Ontario, N6A 5B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.